Biopharma and medtech capital markets built on a steady start to the year, with capital moving toward later-stage assets and established programs. In biopharma, several large licensing deals and two straight quarters of $40 billion-plus M&A pulled venture and IPO activity higher. In medtech, buyer demand kept M&A as the primary exit channel, with venture funding remaining steady but subdued and IPO activity selective. Biopharma M&A totaled $96 billion across 80 deals in H1 2026, with $55.1 billion from 48 deals in Q2. Medtech M&A reached $48.9 billion across 92 deals, including $22.3 billion from 47 deals in Q2.
Read the full article: Biopharma and Medtech Activity in Q2 2026 //
Source: https://www.jpmorgan.com/insights/markets-and-economy/outlook/biopharma-medtech-deal-reports